This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Borden EC , Baker LH , Bell RS , Bramwell V , Demetri GD , Eisenberg BL , Fletcher CD , Fletcher JA , Ladanyi M , Meltzer P , O'Sullivan B , Parkinson DR , Pisters PW , Saxman S , Singer S , Sundaram M , Van Oosterom AT , Verweij J , Waalen J , Weiss SW , Brennan MF
Soft tissue sarcomas of adults: state of the translational science
Clin Cancer Res. 2003 Jun;9(6) :1941-56
PMID: 12796356 URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12796356
AbstractSarcomas-like leukemias, which are also mesodermal malignancies-carry biological significance disproportionate to their clinical frequency. Identification of mutations and translocations associated with these tumors has illuminated aberrant signaling pathways that cause these diseases, determine their behavior, and are therapeutic targets. Activated receptor-associated tyrosine kinase c-kit, mutated in most gastrointestinal stromal tumors, has proven a clinically effective target for enzyme inhibition. A translocation involving a single gene family, consisting of EWS and related genes, has been identified in five different sarcomas, and its chimeric protein products could prove similarly amenable to inhibitors. Resolution of the histopathological complexity is being aided by data from molecular and chromosomal characterization. Improvements in imaging, definition of prognostic factors, and surgical and radiotherapeutic treatment have resulted in improved local control. Continued progress will depend on further adapting the rapidly evolving technologies of genomics and proteomics. It will also depend upon accurate histopathological diagnosis based on validated reagents and consistent methodologies applied to adequate tissue samples derived from patients with complete clinical data. Finally, multicenter, coordinated trials, such as those that occurred with assessment of imatinib mesylate in metastatic gastrointestinal stromal tumors, will assure the most rapid reductions in morbidity and mortality.
Notes22680806 1078-0432 Journal Article